422 related articles for article (PubMed ID: 37376053)
1. The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies.
Laface C; Maselli FM; Santoro AN; Iaia ML; Ambrogio F; Laterza M; Guarini C; De Santis P; Perrone M; Fedele P
Pharmaceutics; 2023 May; 15(6):. PubMed ID: 37376053
[TBL] [Abstract][Full Text] [Related]
2. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
3. Next-Generation
Sullivan I; Planchard D
Front Med (Lausanne); 2016; 3():76. PubMed ID: 28149837
[TBL] [Abstract][Full Text] [Related]
4. Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence.
Wang X; Goldstein D; Crowe PJ; Yang JL
Onco Targets Ther; 2016; 9():5461-73. PubMed ID: 27660463
[TBL] [Abstract][Full Text] [Related]
5. Molecular Mechanism of EGFR-TKI Resistance in
Reita D; Pabst L; Pencreach E; Guérin E; Dano L; Rimelen V; Voegeli AC; Vallat L; Mascaux C; Beau-Faller M
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638411
[TBL] [Abstract][Full Text] [Related]
6. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
7. First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive
Takeda M; Nakagawa K
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30609789
[TBL] [Abstract][Full Text] [Related]
8. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Andrews Wright NM; Goss GD
Transl Lung Cancer Res; 2019 Nov; 8(Suppl 3):S247-S264. PubMed ID: 31857949
[TBL] [Abstract][Full Text] [Related]
9. Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.
Proto C; Lo Russo G; Corrao G; Ganzinelli M; Facchinetti F; Minari R; Tiseo M; Garassino MC
Tumori; 2017 Jul; 103(4):325-337. PubMed ID: 28708233
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy.
Nagano T; Tachihara M; Nishimura Y
Cells; 2018 Nov; 7(11):. PubMed ID: 30445769
[TBL] [Abstract][Full Text] [Related]
11. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations.
Hayashi H; Nadal E; Gray JE; Ardizzoni A; Caria N; Puri T; Grohe C
Clin Lung Cancer; 2022 Jan; 23(1):e69-e82. PubMed ID: 34865963
[TBL] [Abstract][Full Text] [Related]
12. First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis.
Chen C; Zhang C; Lin H; Liu Q; Wu L; Zhou C; Zhang J
Ther Adv Chronic Dis; 2022; 13():20406223221125706. PubMed ID: 36274751
[TBL] [Abstract][Full Text] [Related]
13. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies.
Johnson M; Garassino MC; Mok T; Mitsudomi T
Lung Cancer; 2022 Aug; 170():41-51. PubMed ID: 35714425
[TBL] [Abstract][Full Text] [Related]
14. Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs).
Mountzios G
Ann Transl Med; 2018 Apr; 6(8):140. PubMed ID: 29862229
[TBL] [Abstract][Full Text] [Related]
15. An Observational Study of Acquired
Wu SG; Chiang CL; Liu CY; Wang CC; Su PL; Hsia TC; Shih JY; Chang GC
Front Oncol; 2020; 10():1481. PubMed ID: 33014788
[TBL] [Abstract][Full Text] [Related]
16. [Treatment strategy for activating EGFR-mutated non-small cell lung cancer after failure of first-generation EGFR-TKIs].
Asami K
Gan To Kagaku Ryoho; 2014 May; 41(5):533-8. PubMed ID: 24916999
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
Santarpia M; Liguori A; Karachaliou N; Gonzalez-Cao M; Daffinà MG; D'Aveni A; Marabello G; Altavilla G; Rosell R
Lung Cancer (Auckl); 2017; 8():109-125. PubMed ID: 28860885
[TBL] [Abstract][Full Text] [Related]
18. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
19. Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations.
Hsu PC; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Wu CE
Ther Adv Respir Dis; 2022; 16():17534666221132731. PubMed ID: 36305280
[TBL] [Abstract][Full Text] [Related]
20. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]